|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-jRCTs031180220 |
|
Date of registration:
|
15/03/2019 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Rituximab treatment of blistering disease
|
|
Scientific title:
|
Treatment of refractory autoimmuno blistering disease with rituximab |
|
Date of first enrolment:
|
01/05/2014 |
|
Target sample size:
|
10 |
|
Recruitment status: |
Complete |
|
URL:
|
https://jrct.niph.go.jp/latest-detail/jRCTs031180220 |
|
Study type:
|
Interventional |
|
Study design:
|
non-randomized controlled trial, open(masking not used), uncontrolled control, single assignment, treatment purpose
|
|
Phase:
|
N/A
|
|
|
Contacts
|
|
Name:
|
Miwa
Kanaoka |
|
Address:
|
3-9 Fukuura, Kanazawa-ku, Yokohama
221-0004
Kanagawa
Japan |
|
Telephone:
|
+81-45-787-2800 |
|
Email:
|
kanaokam@yokohama-cu.ac.jp |
|
Affiliation:
|
Yokohama City University Hospital |
|
|
Name:
|
Miwa
Kanaoka |
|
Address:
|
3-9 Fukuura, Kanazawa-ku, Yokohama
221-0004
Kanagawa
Japan |
|
Telephone:
|
+81-45-787-2800 |
|
Email:
|
kanaokam@yokohama-cu.ac.jp |
|
Affiliation:
|
Yokohama City University Hospital |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Patients who were diagnosed with pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid, with sufficient explanation and obtained research consent as sentences.
Exclusion criteria: Patients diagnosed as inappropriate by the judgment of the doctor.
Age minimum:
>= 20age old
Age maximum:
< 80age old
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Pemphigus vulgaris, paraneoplastic pemphigus, bullous pemphigoid
|
|
Intervention(s)
|
|
Infusion of rituximab (1000mg) intravenously. Approximately two weeks after the first dose, a second dose of rituximab is administered in a similar manner.
|
|
Primary Outcome(s)
|
|
Reduction of immunosuppressive agent and steroid dose.
|
|
Secondary Outcome(s)
|
|
Improvement of clinical symptoms, reduction of antibody titer.
|
|
Source(s) of Monetary Support
|
|
Ethics review
|
Status: Approval
Approval date:
Contact:
rinri@yokohama-cu.ac.jp
Yokohama City University Certified Institutional Review Board
+81-45-370-7627
rinri@yokohama-cu.ac.jp
|
|
Results
|
|
Results available:
|
Yes |
|
Date Posted:
|
31/03/2023 |
|
Date Completed:
|
01/12/2020 |
|
URL:
|
|
|
|